본문으로 건너뛰기
← 뒤로

CD137 in tuberculosis: a scoping review of an emerging immune checkpoint at the crossroads of diagnosis, prognosis, and therapy.

리뷰 1/5 보강
Frontiers in immunology 📖 저널 OA 100% 2021: 2/2 OA 2022: 13/13 OA 2023: 10/10 OA 2024: 62/62 OA 2025: 810/810 OA 2026: 522/522 OA 2021~2026 2025 Vol.16() p. 1682269
Retraction 확인
출처

Nasir Goronyo N, Chendi BH, Naidoo S, Chegou NN

📝 환자 설명용 한 줄

[INTRODUCTION] CD137 (4-1BB), a member of the tumour necrosis factor (TNF) receptor superfamily, plays a key role in T-cell activation, survival, and cytokine production, functions that are central to

이 논문을 인용하기

↓ .bib ↓ .ris
APA Nasir Goronyo N, Chendi BH, et al. (2025). CD137 in tuberculosis: a scoping review of an emerging immune checkpoint at the crossroads of diagnosis, prognosis, and therapy.. Frontiers in immunology, 16, 1682269. https://doi.org/10.3389/fimmu.2025.1682269
MLA Nasir Goronyo N, et al.. "CD137 in tuberculosis: a scoping review of an emerging immune checkpoint at the crossroads of diagnosis, prognosis, and therapy.." Frontiers in immunology, vol. 16, 2025, pp. 1682269.
PMID 41256867 ↗

Abstract

[INTRODUCTION] CD137 (4-1BB), a member of the tumour necrosis factor (TNF) receptor superfamily, plays a key role in T-cell activation, survival, and cytokine production, functions that are central to immune responses against . This scoping review brings together current evidence on the clinical relevance of CD137 in tuberculosis (TB), including its potential as a diagnostic, prognostic, and therapeutic target.

[METHODS] This review was conducted in accordance with the PRISMA extension for Scoping Reviews (PRISMA-ScR). Relevant studies on CD137 in TB were identified through database searches and screened using predefined eligibility criteria. Experimental, animal, and human studies reporting on CD137 expression, function, or clinical associations were included. Key information from each study was charted to describe the scope, characteristics, and main findings of the available evidence.

[RESULTS] We identified ten eligible studies involving experiments, animal models, and human cohorts. CD137-positive T cells and soluble CD137 (sCD137) levels were consistently elevated in active TB, with some evidence suggesting the ability to distinguish disease states and predict severity. Mechanistic studies show that CD137 modulates cytokine responses, including interferon-gamma (IFN-γ) and TNF-α, and interacts with other immune checkpoints such as programmed cell death protein-1 (PD-1) and cytotoxic T-lymphocyte-associated protein-4 (CTLA-4). Preclinical models have demonstrated that CD137-targeted strategies may enhance mycobacterial control. Although current findings are promising, most studies are small, geographically limited, and exploratory.

[DISCUSSION] CD137 remains an underexplored immune checkpoint with potential to inform host-directed TB diagnostics and therapies, offering a new angle for precision immunology in high-burden settings. Large-scale, longitudinal studies are needed to define its role in host immunity and determine its translational value.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반

🟢 PMC 전문 열기